8-K filed Nov 5, 2026 at 08:08 ET
Novavax reported Q3 2026 total revenue of $68M, a 3% decline from $70M in Q3 2025, and a GAAP net loss of $31M (improved from a $202M loss a year ago). The company raised its full-year 2026 Adjusted Total Revenue guidance by $145M at the midpoint to $385M-$415M, driven by a $125M milestone earned from Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial initiation. The net loss narrowed sharply due to reduced R&D and SG&A expenses.